In 2020 76 biotech floats raised a combined $12.7bn. Foghorn is not the first to show that much of the faith was misplaced.
Amcenestrant flunks the long-delayed Ameera-3 trial in ER-positive Her2-negative breast cancer, so how much blame can be put on poor study design?
Trial design comes into focus as late-stage readouts loom for Sanofi, Roche and Astrazeneca.
The French group was to have been first to report key Serd data this year, but has suffered delays as Roche and now Radius beat it to the punch.
Selective oestrogen degraders, or Serds, remain in focus as a key period for reporting clinical data approaches.
Late-stage data are expected for Apellis; Ionis and Biogen tackle ALS; and Mirati awaits combination results.
The most important of this year’s two virtual AACRs features immunotherapy combos, new Kras players and first clinical data for several assets.